Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Chronic Idiopathic Urticaria
Interventions: AZD1981, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Skin Biopsy, Skin tape stripping, Blood draw; Procedure
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis
Interventions: Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 27 Years to 43 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: San Diego, California • Denver, Colorado • Portland, Oregon

Conditions: Includes: Hereditary Angioedema
Interventions: Berinert® (C1 Esterase Inhibitor); Biological
Lead sponsor: CSL Behring; Industry
Eligibility: Not listed
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 34
States / cities: Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 31 more

Conditions: Rosacea
Interventions: Coppertone, BAY1183345; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Dermatitis, Atopic
Interventions: Spesolimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Cyclosporine A; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Choroiditis, Iridocyclitis, Iritis, Retinal Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 4 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriasis, Atopic Dermatitis
Interventions: CT-100-004-A, CT-100-004-B; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Online Teledermatology Care, Conventional in Office Care; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 4 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Atopic Dermatitis
Interventions: ENV-294, Placebo; Drug · Other
Lead sponsor: Enveda Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Encinitas, California • Los Angeles, California • Northridge, California + 6 more

Conditions: Smallpox, Atopic Dermatitis
Interventions: MVA (smallpox vaccine); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Portland, Oregon • Austin, Texas

Conditions: Atopic Dermatitis
Interventions: Cetaphil Restoraderm, Standard of Care; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Day to 3 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetic Ulcers
Interventions: Vasculera; Dietary Supplement
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 25 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Irritable Bowel Syndrome
Interventions: True avoidance diet, Sham avoidance diet; Other
Lead sponsor: IBS-80, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: North Wales, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Hormone-Sensitive Breast Cancer, Breast Cancer
Interventions: Letrozole, Bevacizumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Migraine
Interventions: Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Allergy Skin, Allergy, Dermatitis, Allergic Contact
Interventions: NeoMatriX Wound MatriX Collagen Dressing; Device
Lead sponsor: NeXtGen Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions: Palifermin; Drug
Lead sponsor: Brett King; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Bridgeport, Connecticut • New Haven, Connecticut

Conditions: Respiratory Disease, Inflammation, Insufficient Sleep, Digestive Disease, Skin Conditions, Body Mass Index, Infections, Allergies, Congestion, Antibiotic Use, Overweight and Obesity
Interventions: Attachment and Biobehavioral Catch-Up, Home-Based Book-of-the-Week; Behavioral · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 8 Months to 12 Months
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions: Maskin Probe; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more

Search by objective public record fields.

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

Identification of Epidermal Signatures in Patients With Atopic Dermatitis

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

Patient Registry Study of Berinert® in Normal Clinical Practice

4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

Evaluation and Treatment of Patients With Inflammatory Eye Diseases

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers

IBS Skin Patch Test Food Allergy Study

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor